Medindia8d
New England Journal of Medicine Publishes Results of Global, Multicenter eNRGy Study Evaluating Zenocutuzumab-zbco (BIZENGRI®) in NRG1+ cancer
New England Journal of Medicine Publishes eNRGy Trial Evaluating Zenocutuzumab-zbco (BIZENGRI®) in NRG1+ cancer ...
New England Journal Of Medicine Publishes: Efficacy Of Zenocutuzumab In NRG1 Fusion-Positive Cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinic ...
Daily12h
Parathyroidectomy Tied to Early Improvement in Inflammatory and Cardiovascular Risk Factors in PHPT: Study
Turkey: A recent retrospective study explored the effects of parathyroidectomy (PTX) on inflammatory and cardiovascular risk ...
Frontiers12d
Better together: nanoscale co-delivery systems of therapeutic agents for high-performance cancer therapy
This approach underscores a move toward more personalized and precise medical treatments, where the choice of delivery ... mesoporous silica nanoparticle platform for synergistic GEM and PTX delivery ...
The Victoria Advocate10d
New England Journal of Medicine Publishes Results of Global, Multicenter eNRGy Study Evaluating Zenocutuzumab-zbco (BIZENGRI®) in NRG1+ cancer
LEXINGTON, Mass., Feb. 5, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company announced today that the New England Journal of Medicine (NEJM ...
ascopubs.org19d
Results of a phase 2 trial of ramucirumab plus docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903).
Prediction of relapse-free survival in stage III gastric cancer patients treated with postoperative adjuvant chemotherapy: Random survival forest analysis from the START-2 trial. This is an ASCO ...
Medscape3d
Medical Students
Doctors and their patients discuss the range of services that Duke Cancer Institute provides to teens and younger adults with a history of cancer. Beyond Cancer: Mental Health and Therapy Duke ...